SCL Science Inc. (246960.KQ)
KOSDAQ · KRW · Healthcare · Medical Devices
₩2,310 (+1.09%) as of
Key statistics
- Market cap
- 78.57B
- Dividend yield
- 0.00%
- 52-week range
- 1,389.00 – 2,940.00
- Beta
- 0.53
- Revenue (TTM)
- 30.5B
- Profit margin
- -11.10%
- Volume
- 79.06k
About SCL Science Inc.
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK and InTro vascular interventional procedure items; and operates bio-logistics business. The company also engages in conducting clinical trial analysis services related to new drug development, in vitro diagnostic medical device performance evaluation, transportation of pharmaceuticals and clinical trial samples, etc. The company was formerly known as InnoTherapy, Inc. and changed its name to SCL Science Inc. in March 2024. SCL Science Inc. was founded in 2010 and is headquartered in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Seoul, South Korea
- Employees
- 159
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.